Healthcare

Roivant Sciences is a biotech platform built around developing and managing specialized drug subsidiaries. Its most compelling angle is the combination of a strong balance sheet, active portfolio reshaping, and meaningful upside tied to late-stage immunology programs.

Regeneron is a profitable biotech leader built on blockbuster medicines, deep antibody research, and a very strong balance sheet. The key attraction is its ability to fund future growth internally while expanding major franchises and advancing a broad pipeline.

BeiGene has become a large commercial oncology company built around BRUKINSA, with fast revenue growth, improving margins, and positive free cash flow. Its shift from heavy losses to profitability makes its long-term profile far more substantial than a typical biotech.

Natera develops genetic tests for cancer care, prenatal screening, and transplant monitoring. Its rapid shift toward oncology, strong revenue growth, improving cash generation, and lighter debt load make it one of the more closely watched names in precision diagnostics.

Mettler-Toledo makes precision instruments for labs, factories, and retail users. Its appeal rests on essential products, recurring service revenue, strong margins, and exceptional returns on capital, while recent sales recovery adds another layer of interest to the long-term picture.

Moderna is trying to evolve from a pandemic-era vaccine winner into a broader mRNA medicines company. Its scale, cash resources, and late-stage pipeline create real upside, but the key question is whether new products can replace lost COVID earnings.

McKesson is a healthcare distribution giant that turns enormous scale into steady cash flow. Its reach in pharmaceuticals, growing oncology presence, and expanding specialty capabilities make it an important company to examine for long-term business durability.